Cost-utility and budget impact analysis of biosimilar trastuzumab for early-stage HER2-positive breast cancer in Thailand: an updated evaluation supporting expanded access | Synapse
March 3, 2026Open Access
Cost-utility and budget impact analysis of biosimilar trastuzumab for early-stage HER2-positive breast cancer in Thailand: an updated evaluation supporting expanded access
Puntos clave
Biosimilar trastuzumab shows improved cost-utility for treating HER2-positive breast cancer, making it a viable alternative.
The analysis indicates a budget impact that supports wider access to biosimilar treatments in Thailand.
Evaluation utilized cost-utility analysis to assess financial and health outcomes of biosimilar trastuzumab.
Wider access to the biosimilar could reduce financial burdens on patients, highlighting the need for policy consideration.